1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow Long QT syndrome type 3: new trials by email Literature Review of Long QT syndrome type 3 trials Research Report on Long QT syndrome type 3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3 Eleclazine, Eleclazine placebo - Long QT Syndrome Type 3 | Phase 3 | Terminated | Gilead Sciences | 41 | 2014-12-17 | 2018-01-12 |
Death, Sudden, Cardiac (1) · Long QT Syndrome (1)
Arrhythmias, Cardiac (1) · Cardiac Conduction System Disease (1) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Death (1) · Death, Sudden (1) · Heart Arrest (1) · Heart Defects, Congenital (1) · Heart Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
eleclazine (1)
Gilead Sciences (1)
Canada (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · United Kingdom (1) · United States (1)
2014 (1)